Stay updated on Pembrolizumab for HR+ Inflammatory Breast Cancer Clinical Trial

Sign up to get notified when there's something new on the Pembrolizumab for HR+ Inflammatory Breast Cancer Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Pembrolizumab for HR+ Inflammatory Breast Cancer Clinical Trial page

  1. Check
    yesterday
    No Change Detected
  2. Check
    8 days ago
    Change Detected
    Summary
    The web page has been updated from version 2.15.0 to version 2.15.2, indicating a revision in the content.
    Difference
    0.1%
    Check dated 2025-05-01T04:29:40.000Z thumbnail image
  3. Check
    15 days ago
    No Change Detected
  4. Check
    23 days ago
    Change Detected
    Summary
    The webpage has undergone significant changes, including the removal of detailed information about a Phase II trial involving pembrolizumab for treating inflammatory breast cancer, while adding new identifiers and collaborators related to the study.
    Difference
    51%
    Check dated 2025-04-16T14:37:24.000Z thumbnail image
  5. Check
    30 days ago
    Change Detected
    Summary
    The page has been updated to reflect the latest version as v2.14.4, replacing the previous version v2.14.3. The estimated last update posted has been removed.
    Difference
    0.1%
    Check dated 2025-04-09T09:28:25.000Z thumbnail image
  6. Check
    73 days ago
    Change Detected
    Summary
    The page has removed a notice regarding heavy traffic affecting the performance and availability of some NLM-NCBI services and products.
    Difference
    1%
    Check dated 2025-02-24T20:50:21.000Z thumbnail image
  7. Check
    81 days ago
    Change Detected
    Summary
    The webpage has updated its date references, removing older dates from September 2024 and replacing them with new dates in February 2025.
    Difference
    0.9%
    Check dated 2025-02-17T15:22:19.000Z thumbnail image
  8. Check
    88 days ago
    Change Detected
    Summary
    The page now includes a notice regarding heavy traffic affecting the performance and availability of some NLM-NCBI services and products, along with contact information for assistance.
    Difference
    1%
    Check dated 2025-02-10T09:53:05.000Z thumbnail image

Stay in the know with updates to Pembrolizumab for HR+ Inflammatory Breast Cancer Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Pembrolizumab for HR+ Inflammatory Breast Cancer Clinical Trial page.